SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63389 357 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
61207re: GILD and Trodelvy. 'Sales of the drug rose 90% to $305 million in the ferickerickson610/11/2022
61206I think this is Q2 data, so not new news. But interesting.bodish-10/11/2022
61205Not sure if any of this is news but happened to see it. The Vanguard Group, Incsysiphus310/11/2022
61204Gilead's Trodelvy gets FDA priority review for expanded use in breast cancerDavidoff810/11/2022
61203Annovis trial data publication: Buntanetap phase 2a trial It is promising an thscorman1-10/11/2022
61202SRPT presents some new data: Sarepta Therapeutics Presents New Data from its Geerickerickson210/7/2022
61201"Caregiver freedom" in itself is invaluable. In each of these four patghettogoulash-10/7/2022
61200The difference is with Calvin and Martha, there was no other data to support effghettogoulash-10/6/2022
61199SAVA springer bit: Reminds me Calvin and Martha, feel-good and encouraging, buterickerickson210/6/2022
61198So just for yucks I looked to see whether SAVA had any news lately. The usual flerickerickson-10/6/2022
61197SAVA: this Springer video is worth watching. you can start at the 6:25 mark ...plhky3465110/6/2022
61196I should have said, "Too good to be true, especially when the short sellersghettogoulash-10/4/2022
61195Dr. Robinson actually did comment on the 100-patient readout at 12 months. To meghettogoulash-10/4/2022
61194No matter what you can count on ol’ Joe to spread his heavily tattooed arms out jargonweary110/4/2022
61193Omg now it's 3 doctors and 1 lawyer. We'll see.ghettogoulash-10/4/2022
61192Correction: 1 doctor and 3 attorneys will be interviewed, says Joeghettogoulash-10/4/2022
61191competition from lecanemab ??? SA just reiterated a facet of Biogen's new scorman1-10/4/2022
61190Oh, wait. I see what he is doing. Never mind. Since our baselines are substantighettogoulash-10/4/2022
61189There's a compelling theory that Sanford Robinson's Francisco Partners mghettogoulash-10/3/2022
61188I don't think it is sophistry to make an assessment of a stock's value bghettogoulash110/3/2022
61187The author is Dr. Lewis Robinson. He interviewed with Joe Springer earlier in thghettogoulash-10/3/2022
61186Absolutely correct on the CEO issue; I've said it before and it bears repeatFitzhughlaw-10/3/2022
61185fwiw, I have 2 concerns with SAVA. The first is the obvious one, that the drug dallatwwk210/3/2022
61184Thank you for this data! Very interesting; albeit, some is over my head. Even Davidoff110/2/2022
61183Matt, here's an interesting piece from a blog named CHEMIOTICS II, written bFitzhughlaw510/2/2022
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News